{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:00:36Z","timestamp":1771920036967,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Currently, the prognosis for metastatic colorectal cancer (mCRC) remains unfavorable. However, as advancements in local and systemic treatment modalities progress, therapeutic strategies for mCRC are becoming increasingly varied. For patients presenting with a limited number of metastases, the integration of radical local treatment with systemic therapy holds promise for achieving sustained tumor control. This study seeks to investigate the efficacy and safety of combining microwave ablation (MWA) with fruquintinib and tislelizumab in patients with mCRC.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Between March 2022 and September 2022, a screening process was conducted on patients with advanced colorectal cancer and liver metastases who had previously undergone radical colon cancer surgery at our institution. Eligible patients commenced a combined treatment regimen of fruquintinib (5 mg, administered daily from day 1 to day 14) and tislelizumab (200 mg, administered on day 1 every three weeks) within one week following the completion of MWA. Post-surgery, 21 patients received the combination of fruquintinib, a molecular-targeted therapy, and tislelizumab immunotherapy, whereas 34 patients were administered tislelizumab in conjunction with a placebo as the molecular-targeted treatment. The study evaluated all patients\u2019 progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and three-year overall survival (OS).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the study, the median PFS was 13.2 months for the experimental group compared to 7.35 months for the control group, with 1-year PFS rates of 66.7% and 23.5%, respectively. Tislelizumab monotherapy emerged as an independent risk factor for tumor recurrence, with the experimental group exhibiting a 0.184-fold reduction in recurrence risk relative to the control group (P = 0.036). Multivariate Cox regression analysis further identified elevated carcinoembryonic antigen levels and the number of liver metastases as significant risk factors for tumor recurrence. Specifically, patients with normal carcinoembryonic antigen levels demonstrated a 0.12-fold lower recurrence risk compared to those with elevated levels (P = 0.0002), while patients with a single liver metastasis had a 0.208-fold lower recurrence risk than those with multiple metastases (P = 0.0003). The ORR were 72.5% in the experimental group and 58.8% in the control group, indicating a significantly higher ORR in the experimental group. Additionally, the experimental group exhibited superior OS compared to the control group, with both groups achieving an OS exceeding 20 months.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This study aims to provide novel clinical evidence supporting the integration of MWA with PD-1 inhibitors and anti-angiogenic agents in the systemic management of mCRC. It is anticipated that these findings will expand therapeutic options available to patients.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n https:\/\/www.chictr.org.cn\/showproj.html?proj=140822<\/jats:ext-link>\n , identifier ChiCTR 2200058323 (China Clinical Trial Center).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1728876","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:18:46Z","timestamp":1771910326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huatang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juntong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyi","family":"Pen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cantu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jincheng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5978131","DOI":"10.1155\/2020\/5978131","article-title":"RUNX3 inhibits the invasion and metastasis of human colon cancer HT-29 cells by upregulating MMP-2\/9","volume":"2020","author":"Xue","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae276","article-title":"Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma","volume":"30","author":"Choi","year":"2025","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.346","article-title":"First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study","volume":"111","author":"Feliu","year":"2014","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6686517","DOI":"10.1155\/2021\/6686517","article-title":"UGT1A1 polymorphism for irinotecan dose escalation in patients with BRAF-mutated metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI","volume":"2021","author":"Hsieh","year":"2021","journal-title":"J Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e996","DOI":"10.1016\/S2468-2667(23)00186-X","article-title":"Cancer screening in China: a steep road from evidence to implementation","volume":"8","author":"Xia","year":"2023","journal-title":"Lancet Public Health"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153766","article-title":"Salvage nodal radiotherapy as metastasis-directed therapy for oligorecurrent prostate cancer detected by positron emission tomography shows favorable outcome in long-term follow-up","volume":"14","author":"Tamihardja","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1038\/s41598-021-81913-1","article-title":"Comparison of deep and moderate neuromuscular blockade in microwave ablation of liver tumours: a randomized-controlled clinical trial","volume":"11","author":"Loh","year":"2021","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S404424","article-title":"Egyptian society of liver cancer recommendation guidelines for the management of hepatocellular carcinoma","volume":"10","author":"Omar","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051305","article-title":"Microwave ablation for colorectal liver metastases: A systematic review and pooled oncological analyses","volume":"14","author":"Mimmo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.885670","article-title":"Editorial: tumor vessels as directors of the tumor microenvironment: new findings, current challenges & Perspectives","volume":"10","author":"Treps","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2050879495","DOI":"10.1177\/15330338251345913","article-title":"Sintilimab + Nab-PP combined with recombinant human vascular endothelial inhibitor for locally advanced\/advanced and recurrent metastatic squamous non-small cell lung cancer: study protocol for a single-arm, multi-centre phase II clinical study","volume":"24","author":"Xu","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-23-677","article-title":"Radiofrequency ablation versus microwave ablation for colorectal liver metastases: long-term results of a retrospective cohort surgical experience","volume":"13","author":"Sarioglu","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2021.1941311","article-title":"Thermal ablation in the management of oligometastatic colorectal cancer","volume":"39","author":"De Baere","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2022.09.004","article-title":"The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex Scanning and Treatment of Superficial Truncal Reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology","volume":"11","author":"Gloviczki","year":"2023","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2200582","DOI":"10.1080\/02656736.2023.2200582","article-title":"Interventional oncological treatment of breast cancer liver metastasis (BCLM): single center long-term evaluation over 26 years using thermoablation techniques like LITT, MWA and TACE in a multimodal application","volume":"40","author":"Vogl","year":"2023","journal-title":"Int J Hyperthermia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071197","article-title":"Technical feasibility of microwave ablation in pancreatic tumors: A scoping review of procedural efficacy and safety","volume":"17","author":"Tabacelia","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13525","DOI":"10.1097\/MD.0000000000013525","article-title":"Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long-term survival: Systematic review and pooled analysis","volume":"97","author":"Tang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1066990","article-title":"Thermal ablation in pancreatic cancer: A scoping review of clinical studies","volume":"12","author":"Farmer","year":"2022","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2020.1853942","article-title":"Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice","volume":"19","author":"Duan","year":"2020","journal-title":"Cell Cycle"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16182","article-title":"Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity","volume":"115","author":"He","year":"2024","journal-title":"Cancer Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-940","article-title":"PD-1 blockade combined with chemotherapy and bevacizumab in DNA mismatch repair-proficient\/microsatellite stable colorectal liver metastases","volume":"15","author":"Men","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2006.9014","article-title":"FDG-PET in colorectal cancer","volume":"6","author":"de Geus-Oei","year":"2006","journal-title":"Cancer Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.remnie.2019.12.001","article-title":"FDG PET\/CT in colorectal cancer","volume":"39","author":"Rodriguez-Fraile","year":"2020","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-24-559","article-title":"Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors","volume":"15","author":"Wang","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.45.3.186","article-title":"Prognostic significance of serum carcinoembryonic antigen normalization on survival in rectal cancer treated with preoperative chemoradiation","volume":"45","author":"Chung","year":"2013","journal-title":"Cancer Res Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab086","article-title":"Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status","volume":"108","author":"Kawaguchi","year":"2021","journal-title":"Br J Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001371","article-title":"Lung metastases after liver cancer resection cured by immunotherapy: case report and literature review","volume":"34","author":"Ou","year":"2023","journal-title":"Anticancer Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/02656736.2018.1528511","article-title":"The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center","volume":"36","author":"Qin","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae360","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2","volume":"30","author":"Eng","year":"2025","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1728876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:18:47Z","timestamp":1771910327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1728876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1728876"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1728876","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1728876"}}